Zhitong Finance App News, Shiyao Group (01093.HK) announced that SYS 6010 (“this product”) developed by the Group was recently included in the list of breakthrough treatment varieties by the China Drug Administration (“State Drug Administration”). The proposed indications are recurrent or metastatic negative non-squamous non-small cell lung cancer that has previously received immunotherapy and failed platinum-containing chemotherapy.

Zhitong Finance App News, Shiyao Group (01093.HK) announced that SYS 6010 (“this product”) developed by the Group was recently included in the list of breakthrough treatment varieties by the China Drug Administration (“State Drug Administration”). The proposed indications are recurrent or metastatic negative non-squamous non-small cell lung cancer that has previously received immunotherapy and failed platinum-containing chemotherapy.